BR112021023900A2 - Compostos e composições farmacêuticas dos mesmos para o tratamento de doenças - Google Patents
Compostos e composições farmacêuticas dos mesmos para o tratamento de doençasInfo
- Publication number
- BR112021023900A2 BR112021023900A2 BR112021023900A BR112021023900A BR112021023900A2 BR 112021023900 A2 BR112021023900 A2 BR 112021023900A2 BR 112021023900 A BR112021023900 A BR 112021023900A BR 112021023900 A BR112021023900 A BR 112021023900A BR 112021023900 A2 BR112021023900 A2 BR 112021023900A2
- Authority
- BR
- Brazil
- Prior art keywords
- diseases
- treatment
- compounds
- pharmaceutical compositions
- hypersecretion
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 10
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 101150033527 TNF gene Proteins 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000010072 bone remodeling Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
compostos e composições farmacêuticas dos mesmos para o tratamento de doenças. a presente invenção refere-se a compostos de acordo com a fórmula (i), em que r1a, r1b, r1c, r2a, w1, w2, x1, x2, x3, y, e z são como definidos aqui. a presente invenção refere-se a compostos, métodos para sua produção, composições farmacêuticas que compreendem os mesmos e métodos de tratamento usando os mesmos, para a profilaxia e/ou tratamento de doenças inflamatórias, doenças autoinflamatórias, doenças autoimunes, doenças proliferativas, doenças fibróticas, rejeição de transplantes, doenças envolvendo comprometimento da remodelação da cartilagem, malformação de cartilagem congênita, doenças envolvendo comprometimento da remodelação óssea, doenças associadas à hipersecreção de il-6, doenças associadas à hipersecreção de tnfa, interferons, il-12 e/ou il-23, doenças respiratórias, doenças endócrinas e/ou metabólicas, doenças cardiovasculares, doenças dermatológicas, e/ou doenças associadas à angiogênese anormal administrando o composto da invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907616.5A GB201907616D0 (en) | 2019-05-29 | 2019-05-29 | Novel compounds and pharmaceutical compositons thereof for the treatment of diseases |
| PCT/EP2020/064368 WO2020239658A1 (en) | 2019-05-29 | 2020-05-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023900A2 true BR112021023900A2 (pt) | 2022-01-18 |
Family
ID=67385363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023900A BR112021023900A2 (pt) | 2019-05-29 | 2020-05-25 | Compostos e composições farmacêuticas dos mesmos para o tratamento de doenças |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220340548A1 (pt) |
| EP (1) | EP3976189B1 (pt) |
| JP (1) | JP7550174B2 (pt) |
| KR (1) | KR20220015450A (pt) |
| CN (1) | CN113924146A (pt) |
| AR (1) | AR119028A1 (pt) |
| AU (1) | AU2020281650A1 (pt) |
| BR (1) | BR112021023900A2 (pt) |
| CA (1) | CA3141683A1 (pt) |
| CL (1) | CL2021003133A1 (pt) |
| CO (1) | CO2021017656A2 (pt) |
| CR (1) | CR20210586A (pt) |
| EA (1) | EA202193281A1 (pt) |
| GB (1) | GB201907616D0 (pt) |
| IL (1) | IL288375A (pt) |
| MA (1) | MA56019A (pt) |
| MX (1) | MX2021013803A (pt) |
| PE (1) | PE20220503A1 (pt) |
| PL (1) | PL3976189T3 (pt) |
| SG (1) | SG11202112652RA (pt) |
| TW (1) | TW202110839A (pt) |
| WO (1) | WO2020239658A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312955A (en) | 2019-03-11 | 2024-07-01 | Inflarx Gmbh | Fused Piperidinyl Bicyclic Compounds and Related Compounds as C5A Receptor Modulators |
| USD982434S1 (en) * | 2021-08-31 | 2023-04-04 | Level Up Dice LLC | Dice storage container |
| CN118119619A (zh) * | 2021-10-18 | 2024-05-31 | 上海美悦生物科技发展有限公司 | Sik抑制剂及其组合物、制备方法和用途 |
| AR128279A1 (es) * | 2022-01-19 | 2024-04-10 | Hoffmann La Roche | Nuevos derivados de bencimidazol piridina |
| CN115304605B (zh) * | 2022-01-21 | 2023-10-03 | 陕西国际商贸学院 | 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用 |
| WO2024003209A1 (en) * | 2022-07-01 | 2024-01-04 | F. Hoffmann-La Roche Ag | Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis |
| WO2024104441A1 (en) * | 2022-11-17 | 2024-05-23 | Insilico Medicine Ip Limited | Salt-inducible kinases (sik) inhibitors and methods of uses thereof |
| CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2178375B1 (en) * | 2007-07-20 | 2014-09-24 | Merck Sharp & Dohme Corp. | Pyrazoloý1,5-a¨pyrimidine derivatives |
| CN103282034A (zh) * | 2010-11-18 | 2013-09-04 | 利亘制药公司 | 造血生长因子模拟物的用途 |
| EP2646215A1 (en) | 2010-12-01 | 2013-10-09 | Plasan Carbon Composites, Inc. | Method and system for forming composite articles |
| US9512126B2 (en) * | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| WO2017040993A1 (en) | 2015-09-03 | 2017-03-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1a and uses thereof |
| CN106496222A (zh) | 2016-09-07 | 2017-03-15 | 华东师范大学 | 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用 |
| WO2019105886A1 (en) * | 2017-12-02 | 2019-06-06 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CN108358894B (zh) * | 2018-04-26 | 2021-05-07 | 四川大学 | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 |
| MX2020013275A (es) | 2018-06-15 | 2021-02-18 | Galapagos Nv | Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades. |
-
2019
- 2019-05-29 GB GBGB1907616.5A patent/GB201907616D0/en not_active Ceased
-
2020
- 2020-05-25 PL PL20728465.4T patent/PL3976189T3/pl unknown
- 2020-05-25 AU AU2020281650A patent/AU2020281650A1/en active Pending
- 2020-05-25 US US17/614,854 patent/US20220340548A1/en active Pending
- 2020-05-25 KR KR1020217042863A patent/KR20220015450A/ko unknown
- 2020-05-25 CA CA3141683A patent/CA3141683A1/en active Pending
- 2020-05-25 JP JP2021570425A patent/JP7550174B2/ja active Active
- 2020-05-25 EP EP20728465.4A patent/EP3976189B1/en active Active
- 2020-05-25 BR BR112021023900A patent/BR112021023900A2/pt unknown
- 2020-05-25 SG SG11202112652RA patent/SG11202112652RA/en unknown
- 2020-05-25 PE PE2021001955A patent/PE20220503A1/es unknown
- 2020-05-25 MX MX2021013803A patent/MX2021013803A/es unknown
- 2020-05-25 CR CR20210586A patent/CR20210586A/es unknown
- 2020-05-25 EA EA202193281A patent/EA202193281A1/ru unknown
- 2020-05-25 WO PCT/EP2020/064368 patent/WO2020239658A1/en active Application Filing
- 2020-05-25 CN CN202080039185.0A patent/CN113924146A/zh active Pending
- 2020-05-25 MA MA056019A patent/MA56019A/fr unknown
- 2020-05-28 AR ARP200101505A patent/AR119028A1/es unknown
- 2020-05-28 TW TW109117844A patent/TW202110839A/zh unknown
-
2021
- 2021-11-24 IL IL288375A patent/IL288375A/en unknown
- 2021-11-24 CL CL2021003133A patent/CL2021003133A1/es unknown
- 2021-12-22 CO CONC2021/0017656A patent/CO2021017656A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA56019A (fr) | 2022-04-06 |
| TW202110839A (zh) | 2021-03-16 |
| EP3976189B1 (en) | 2024-07-03 |
| EP3976189A1 (en) | 2022-04-06 |
| MX2021013803A (es) | 2021-12-14 |
| CL2021003133A1 (es) | 2022-07-22 |
| US20220340548A1 (en) | 2022-10-27 |
| CA3141683A1 (en) | 2020-12-03 |
| PL3976189T3 (pl) | 2024-09-09 |
| CR20210586A (es) | 2022-01-24 |
| IL288375A (en) | 2022-01-01 |
| JP2022534578A (ja) | 2022-08-02 |
| GB201907616D0 (en) | 2019-07-10 |
| CN113924146A (zh) | 2022-01-11 |
| AU2020281650A1 (en) | 2022-02-03 |
| WO2020239658A1 (en) | 2020-12-03 |
| EP3976189C0 (en) | 2024-07-03 |
| KR20220015450A (ko) | 2022-02-08 |
| PE20220503A1 (es) | 2022-04-07 |
| SG11202112652RA (en) | 2021-12-30 |
| JP7550174B2 (ja) | 2024-09-12 |
| AR119028A1 (es) | 2021-11-17 |
| EA202193281A1 (ru) | 2022-03-01 |
| CO2021017656A2 (es) | 2022-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021023900A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de doenças | |
| PH12020550725A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| PH12020552160A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| CO2020005200A2 (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
| NZ738187A (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| BR112019006113A2 (pt) | métodos de tratamento de distúrbios mitocondriais e metabólicos | |
| BR112017022008A2 (pt) | composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios | |
| BR112021017049A2 (pt) | Derivados de tiazol como inibidores de secreção de proteínas | |
| PH12014502615A1 (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
| MX2013012281A (es) | Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| BR112017013258A8 (pt) | Derivados de 5-[(piperazin-1-il)-3-oxo-propil]-imidazolidina-2,4-diona como inibidores de adamts para o tratamento de osteoartrite | |
| BR112018075415A2 (pt) | composição mastigável macia compreendendo plantago | |
| BR112018006866A2 (pt) | compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos | |
| EP3685840A4 (en) | PHARMACEUTICAL COMPOSITION OF COMPOUNDS FOR TREATING INFLAMMATORY SKIN DISEASES | |
| BR112022012684A2 (pt) | Compostos cíclicos e métodos de uso dos mesmos | |
| BR112021019099A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| PH12019501853A1 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| BR112018076734A2 (pt) | compostos heterocíclicos anti-infecciosos e usos dos mesmos | |
| BR112018003313A2 (pt) | novo derivado de catecol e composição farmacêutica compreendendo o mesmo | |
| BR112017022656A2 (pt) | conservação in vitro de células terapêuticas | |
| BR112021016642A2 (pt) | Derivados de pirazolopiridina como inibidores de pask | |
| LT4041186T (lt) | Bevandenė farmacinė kompozicija, skirta palaikomajam psoriazės gydymui | |
| EP3924324A4 (en) | L-PIPECOLIC ACID COCRYSTAL FROM CANNABIDIOL | |
| BR112021026407A8 (pt) | Composição de ibuprofeno e acetaminofeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |